Fake Xanax, Fentanyl and Orphines: What New Tennessee Drug Testing Reveals

What the October 2026 orphine study found

A research letter published in JAMA Psychiatry on October 7, 2026 examined 14,261 biological specimens submitted to the NPS Discovery early-warning surveillance program from the third quarter of 2020 through the second quarter of 2026. Researchers identified 142 specimens containing an orphine analogue, approximately 1% of the selected specimens.

Cychlorphine appeared in 102 positive specimens, while brorphine appeared in 38. Investigators described an earlier wave involving brorphine and a later wave, beginning in late 2025, dominated by cychlorphine. The detections spanned 22 states. A report from Becker’s Behavioral Health brought renewed attention to the research on October 13.

What these numbers do not mean: The specimens were submitted to a targeted forensic surveillance program, not randomly selected from the Tennessee population. The findings cannot establish the prevalence of orphines among all residents, all street drugs, or all overdoses. A detected drug also does not independently prove that it caused an overdose or death.

What are orphine opioids and cychlorphine?

Orphines are a family of synthetic opioids that act at the body’s mu-opioid receptors. This family includes brorphine and cychlorphine. Some compounds in the family have shown very high potency in laboratory assessments, but the potency of one analogue cannot be assumed to apply to every orphine, street pill, or exposure.

Cychlorphine is also called N-propionitrile chlorphine or cychlorophine in some reporting. A spelling variation does not necessarily indicate a new or separate drug. Because these are largely forensic terms, many people encountering a dangerous opioid may never hear its chemical name.

Why Tennessee appears prominently in the findings

Tennessee accounted for 50 of the 142 orphine-positive specimens (35%), the largest share of any state in the selected data. Illinois accounted for 37, Texas for 14, and Minnesota for 10. These are counts of submitted specimens, not rates per resident or estimates of current drug-market prevalence.

That distinction matters in Nashville, Brentwood, Franklin, Murfreesboro, and other Middle Tennessee communities. The results justify increased awareness of emerging synthetic opioids, but they do not show that 35% of Tennessee opioids contain orphines or that Nashville experienced a new overdose surge in October.

Kentucky has separately warned about cychlorphine. That regional context supports awareness across state lines, but this study should not be interpreted as evidence of a newly confirmed Kentucky outbreak.

Orphines mixed with fentanyl, benzos, and stimulants

A central finding was the frequency of co-detection, meaning a laboratory found an orphine and another drug class in the same specimen. In the orphine-positive group, researchers reported the following:

These categories can overlap, so the percentages should not be added together. They do not show that all the substances were knowingly taken together or that every substance contributed to a medical emergency.

Fake Xanax and benzodiazepines

Counterfeit tablets represented as Xanax may contain unexpected sedatives or opioids. Benzodiazepine-type drugs and opioids can both contribute to profound sedation and impaired breathing. Someone concerned about a pill obtained outside a licensed pharmacy should not rely on its color or stamp to identify it. Our Xanax detox resource discusses benzodiazepine dependence and the dangers of abrupt withdrawal.

Fentanyl and other synthetic opioids

Fentanyl and orphines are different chemical families, even though both can act as opioids. Co-detection with fentanyl-related substances can complicate exposure assessment and overdose response. Learn about medical fentanyl detox in Nashville if ongoing opioid use or dependence is a concern.

Methamphetamine and stimulants

Stimulants do not reliably reverse opioid-induced breathing problems. A person exposed to both a stimulant and an opioid can experience overlapping cardiovascular, neurological, and respiratory risks. Treatment planning should evaluate all substances used, not only the drug the person expected to take.

Can fentanyl test strips detect orphines?

Not reliably. Conventional fentanyl test strips are designed to detect fentanyl or certain related substances, not every synthetic opioid family. The researchers specifically identified orphine-detection gaps and called for better analytical testing and surveillance. A negative fentanyl test strip therefore cannot establish that an unknown powder or counterfeit pill is opioid-free.

Routine hospital drug screens may also miss emerging synthetic opioids. Specialized laboratory testing may be needed to identify a specific analogue. Clinical teams should respond to symptoms and suspected opioid toxicity rather than wait for confirmation from a standard drug screen.

No test result can guarantee that an illicitly manufactured pill or powder is safe.

Overdose symptoms and naloxone response

Orphines can cause opioid toxicity, including dangerous respiratory depression. Warning signs can include inability to wake someone, slow or absent breathing, gurgling sounds, blue or gray lips, and pinpoint pupils. Other drugs in the mixture may change how an overdose presents.

Naloxone acts on opioid receptors and should be used when opioid overdose is suspected. The evidence on optimal dosing for individual emerging orphines is limited, so repeat dosing and advanced medical care may be necessary. Naloxone does not reverse the non-opioid effects of benzodiazepines or stimulants.

Treatment after exposure or opioid dependence in Nashville

A single unexpected exposure does not necessarily mean someone has an opioid use disorder. But repeated opioid use, withdrawal symptoms, cravings, overdose history, or use of multiple substances are reasons to seek an individualized evaluation.

At Live Again Detox, our Nashville team provides medically supervised withdrawal care and helps determine whether further addiction treatment is appropriate. Treatment is based on the person’s actual symptoms and use history, rather than assuming a particular substance from a street name.

Evidence-based medications for opioid use disorder, including buprenorphine and methadone when appropriate, may be part of longer-term treatment planning. Detox alone is not a complete treatment for opioid use disorder, and return to use after reduced tolerance can increase overdose risk.

Frequently asked questions about orphines

Sources and research limitations

1. Zhu DT, Fitzgerald ND, Palamar JJ, Krotulski AJ. Temporal, Geographic, and Polysubstance Patterns in Orphine Analogue Detections. JAMA Psychiatry. Published October 7, 2026. doi:10.1001/jamapsychiatry.2026.3129.
2. Becker’s Behavioral Health. Potent synthetic opioids detected in 22 states. October 13, 2026.
3. CDC: About Naloxone. Opioid-overdose response guidance.

Research interpretation: Targeted forensic specimens do not measure population prevalence, street-pill composition, or causation in individual deaths. This article is educational and requires clinical review before publication.